Assessing Risk of Myelosuppression With PARP Inhibitors in Prostate Cancer With Karan Jatwani, MBBS

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Karan Jatwani, third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center, sat down to discuss his poster on “Risk Assessment of Myelosuppression with PARP Inhibitors in Prostate Cancer: Insights from FAERS.” This is the first study analyzing the relative rates of myelosuppression events across poly-ADP ribose polymerase (PARP) inhibitors specifically in prostate cancer. In this conversation with Dr. Salman Faisal, Dr. Jatwani elaborates on the research, including:

  • Background about the four PARP inhibitors approved for metastatic castration-resistant prostate cancer (CRPC)—olaparib, niraparib, rucaparib, and talazoparib—and their risks of myelosuppressive events
  • His team’s study investigating pharmacovigilance, reporting rate, and reaction outcomes of approved PARP inhibitors for metastatic CRPC in US Food and Drug Administration Adverse Event Reporting System (FAERS)
  • The incidence of myelosuppressive events, including anemia, leukopenia, thrombocytopenia, pancytopenia, myelodysplastic syndrome, and acute myeloid leukemia, that was found
  • Implications for patient selection and vigilant monitoring required to optimize the safety and efficacy of PARP inhibitors in prostate cancer
  • And more!

About Dr. Jatwani

Karan Jatwani, MBBS, is a third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center in Buffalo, New York. His research centers around genitourinary cancers, with a focus on patient outcomes, health disparities, and novel therapeutics.

Related Articles

Responses

Your email address will not be published. Required fields are marked *